Does intrapulmonary administration of a p38 mitogen activated protein kinase inhibitor partially prevent pulmonary inflammation?
These results taken together with earlier studies on systemic administration of p38 MAPK inhibitors in rodents and humans suggest that direct intrapulmonary delivery of a p38 MAPK inhibitor is less effective in inhibiting inflammation and is associated with unexpected procoagulant effects in the bronchoalveolar space.
miR-138 could inhibit the expression of HIF-1a and regulate the apoptosis and migration of ccRCC cells.